Pharma BD Deal Intelligence
Novo Nordisk acquired Dicerna Pharmaceuticals for $3.3B for RNAi therapeutics.
Novo Nordisk snaps up partner Dicerna for $3.3 billion after their 2019 GalXC RNAi technology collaboration proved successful enough across 30+ liver cell…
FDA approves RIVFLOZA (nedosiran), a once-monthly GalXC RNAi therapy, for primary hyperoxaluria type 1 (PH1) -- the lead asset from the Dicerna acquisition…
Source summaries from our enrichment pipeline; follow links for originals.
All 5 sources with sentiment breakdown →
Novo Nordisk acquired Dicerna Pharmaceuticals in an all-cash tender offer at $38.25/share (total equity value ~$3.3B, an ~80% premium), announced November 18, 2021 and completed December 28, 2021. The deal converted a 2019 research collaboration into full ownership of Dicerna's proprietary GalXC and GalXC-Plus RNAi platforms for liver-targeted gene silencing across cardiometabolic, NASH/liver, and rare disease targets. Dicerna was pre-revenue at deal time. The platform thesis was subsequently validated: Dicerna's lead GalXC asset nedosiran was FDA-approved as RIVFLOZA on September 29, 2023 under Novo Nordisk ownership for primary hyperoxaluria type 1 (PH1), and the label was later expanded to children aged 2 and older, giving Novo a marketed RNAi rare-disease product from the acquisition.
| Deal | Year | Value | Outcome |
|---|---|---|---|
| Novo Nordisk A/S / Dicerna Pharmaceuticals, Inc. (this deal) | 2021 | $3.3B | 68 |
| Novo Nordisk A/S / Emisphere Technologies | 2020 | $1.4B | 90 |
| Novo Nordisk A/S / Dicerna Pharmaceuticals, Inc. | 2019 | $3.3B | 88 |
| Novo Nordisk A/S / Vivtex Inc. | 2026 | $2.1B | 69 |
| Novo Nordisk A/S / Forma Therapeutics Holdings Inc. | 2022 | $1.1B | 68 |
| Novo Nordisk A/S / Inversago Pharma | 2023 | $1.1B | 61 |
| Novo Nordisk A/S / Forma Therapeutics Holdings Inc. | 2022 | $1.1B | 58 |
← Browse all deals · How we score deals
More: 2021 deals · Novo Nordisk A/S deals · Metabolic deals